Literature DB >> 24174581

Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.

Myla D Goldman1, Robert W Motl, John Scagnelli, John H Pula, Jacob J Sosnoff, Diego Cadavid.   

Abstract

OBJECTIVE: Identify and validate clinically meaningful Timed 25-Foot Walk (T25FW) performance benchmarks in individuals living with multiple sclerosis (MS).
METHODS: Cross-sectional study of 159 MS patients first identified candidate T25FW benchmarks. To characterize the clinical meaningfulness of T25FW benchmarks, we ascertained their relationships to real-life anchors, functional independence, and physiologic measurements of gait and disease progression. Candidate T25FW benchmarks were then prospectively validated in 95 subjects using 13 measures of ambulation and cognition, patient-reported outcomes, and optical coherence tomography.
RESULTS: T25FW of 6 to 7.99 seconds was associated with a change in occupation due to MS, occupational disability, walking with a cane, and needing "some help" with instrumental activities of daily living; T25FW ≥8 seconds was associated with collecting Supplemental Security Income and government health care, walking with a walker, and inability to do instrumental activities of daily living. During prospective benchmark validation, we trichotomized data by T25FW benchmarks (<6 seconds, 6-7.99 seconds, and ≥8 seconds) and found group main effects on 12 of 13 objective and subjective measures (p < 0.05).
CONCLUSIONS: Using a cross-sectional design, we identified 2 clinically meaningful T25FW benchmarks of ≥6 seconds (6-7.99) and ≥8 seconds. Longitudinal and larger studies are needed to confirm the clinical utility and relevance of these proposed T25FW benchmarks and to parse out whether there are additional benchmarks in the lower (<6 seconds) and higher (>10 seconds) ranges of performance.

Entities:  

Mesh:

Year:  2013        PMID: 24174581      PMCID: PMC3821712          DOI: 10.1212/01.wnl.0000436065.97642.d2

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  38 in total

1.  Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.

Authors:  Craig I Coleman; Diana M Sobieraj; Lawrence N Marinucci
Journal:  Curr Med Res Opin       Date:  2011-11-23       Impact factor: 2.580

2.  Quantifying gait abnormalities in persons with multiple sclerosis with minimal disability.

Authors:  Jacob J Sosnoff; Brian M Sandroff; Robert W Motl
Journal:  Gait Posture       Date:  2012-03-17       Impact factor: 2.840

Review 3.  Assessing walking disability in multiple sclerosis.

Authors:  Bernd C Kieseier; Carlo Pozzilli
Journal:  Mult Scler       Date:  2012-04-24       Impact factor: 6.312

4.  Clinical scales in progressive MS: predicting long-term disability.

Authors:  Libertje V A E Bosma; Jolijn J Kragt; Dirk L Knol; Chris H Polman; Bernard M J Uitdehaag
Journal:  Mult Scler       Date:  2011-08-25       Impact factor: 6.312

5.  Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners.

Authors:  Nicholas G Larocca
Journal:  Patient       Date:  2011       Impact factor: 3.883

6.  Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.

Authors:  A S Drake; B Weinstock-Guttman; S A Morrow; D Hojnacki; F E Munschauer; R H B Benedict
Journal:  Mult Scler       Date:  2009-12-22       Impact factor: 6.312

7.  Pulse pressure is associated with walking impairment in multiple sclerosis.

Authors:  Kevin S Heffernan; Sushant Ranadive; Madeline Weikert; Abbi Lane; Huiman Yan; Bo Fernhall; Robert W Motl
Journal:  J Neurol Sci       Date:  2011-08-06       Impact factor: 3.181

8.  Multiple Sclerosis Walking Scale-12 and oxygen cost of walking.

Authors:  Robert W Motl; Deirdre Dlugonski; Yoojin Suh; Madeline Weikert; Stamatis Agiovlasitis; Bo Fernhall; Myla Goldman
Journal:  Gait Posture       Date:  2010-03-11       Impact factor: 2.840

9.  Quantifying gait impairment in multiple sclerosis using GAITRite technology.

Authors:  Jacob J Sosnoff; Madeline Weikert; Deirdre Dlugonski; Douglas C Smith; Robert W Motl
Journal:  Gait Posture       Date:  2011-04-30       Impact factor: 2.840

10.  Oxygen cost of treadmill and over-ground walking in mildly disabled persons with multiple sclerosis.

Authors:  Robert W Motl; Yoojin Suh; Deirdre Dlugonski; Madeline Weikert; Stamatis Agiovlasitis; Bo Fernhall; Myla Goldman
Journal:  Neurol Sci       Date:  2010-08-27       Impact factor: 3.307

View more
  42 in total

1.  ADSTEP: Preliminary Investigation of a Multicomponent Walking Aid Program in People With Multiple Sclerosis.

Authors:  Douglas N Martini; Eline Zeeboer; Andrea Hildebrand; Brett W Fling; Cinda L Hugos; Michelle H Cameron
Journal:  Arch Phys Med Rehabil       Date:  2018-06-26       Impact factor: 3.966

Review 2.  A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.

Authors:  Hernan Inojosa; Undine Proschmann; Katja Akgün; Tjalf Ziemssen
Journal:  J Neurol       Date:  2019-07-30       Impact factor: 4.849

Review 3.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

4.  Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis.

Authors:  Bryan D Loy; Brett W Fling; Fay B Horak; Dennis N Bourdette; Rebecca I Spain
Journal:  Complement Ther Med       Date:  2018-09-22       Impact factor: 2.446

5.  Understanding walking activity in multiple sclerosis: step count, walking intensity and uninterrupted walking activity duration related to degree of disability.

Authors:  An Neven; Annelien Vanderstraeten; Davy Janssens; Geert Wets; Peter Feys
Journal:  Neurol Sci       Date:  2016-05-20       Impact factor: 3.307

6.  Pulse Width Does Not Influence the Gains Achieved With Neuromuscular Electrical Stimulation in People With Multiple Sclerosis: Double-Blind, Randomized Trial.

Authors:  Awad M Almuklass; Leah Davis; Landon D Hamilton; Jeffrey R Hebert; Enrique Alvarez; Roger M Enoka
Journal:  Neurorehabil Neural Repair       Date:  2018-01-24       Impact factor: 3.919

7.  Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.

Authors:  Myla D Goldman; Melanie D Ward; Robert W Motl; David E Jones; John H Pula; Diego Cadavid
Journal:  Mult Scler       Date:  2016-12-07       Impact factor: 6.312

8.  Motor unit discharge characteristics and walking performance of individuals with multiple sclerosis.

Authors:  Awad M Almuklass; Leah Davis; Landon D Hamilton; Taian M Vieira; Alberto Botter; Roger M Enoka
Journal:  J Neurophysiol       Date:  2018-01-03       Impact factor: 2.714

9.  Quantitative sensory and motor measures detect change overtime and correlate with walking speed in individuals with multiple sclerosis.

Authors:  Kathleen M Zackowski; Joseph I Wang; John McGready; Peter A Calabresi; Scott D Newsome
Journal:  Mult Scler Relat Disord       Date:  2015-01       Impact factor: 4.339

Review 10.  Therapies for mobility disability in persons with multiple sclerosis.

Authors:  Jessica F Baird; Brian M Sandroff; Robert W Motl
Journal:  Expert Rev Neurother       Date:  2018-05-30       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.